Nyxoah to Participate in the Bank of America 2026 Healthcare Conference

About this update from Nyxoah Sa

[{"type":"image","alt":"Nyxoah","displaySize":"","headline":null,"caption":"Nyxoah","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/f090b0134f1a96c88516737ccd77cad1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FbfhsHKC3cqGVKfmi0y0gQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2Mg--/https://media.zenfs.com/en/globenewswire.com/f090b0134f1a96c88516737ccd77cad1","width":300,"height":116}},"lazy":false},{"type":"text","content":"Nyxoah to Participate in the Bank of America 2026 Healthcare Conference","length":76,"tagName":"p"},{"type":"text","content":"Mont-Saint-Guibert, Belgium – April 30, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Bank of America 2026 Healthcare Conference on Wednesday, May 13th, 2026. The Company is scheduled to present at 5:15pm Eastern Time the same day via webcast.","length":502,"tagName":"p"},{"type":"text","content":"A live audio webcast of Nyxoah’s presentation at the conference can be accessed through this LINK. The Company will be available for 1x1 meetings with institutional investors attending the event.","length":195,"tagName":"p"},{"type":"text","content":"About NyxoahNyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.","length":547,"tagName":"p"},{"type":"text","content":"Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of i...

More updates from Nyxoah Sa